Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
高级检索
  • 178 Tumor neoantigen prioritiz...
  • 引用
  • 发送短信
  • 推荐此
  • 打印
  • 导出纪录
    • 导出到 RefWorks
    • 导出到 EndNoteWeb
    • 导出到 EndNote
  • Permanent link
178 Tumor neoantigen prioritization from liquid biopsy whole exome sequencing for selected tumor-infiltrating lymphocyte therapy

178 Tumor neoantigen prioritization from liquid biopsy whole exome sequencing for selected tumor-infiltrating lymphocyte therapy

书目详细资料
Main Authors: Li Liu, Simon Turcotte, Shari Pilon-Thomas, Doris Wiener, Brian Czerniecki, Matthew Beatty, Larissa Pikor, Urminder Singh, Christian E Laing, Jacob Gibson, Anna Kluew, Mahdi Golkaram, Sven Bilke, Nathalie Brassard, Stewart E Abbot, Timothy J Langer, Grace DeSantis, Michael J Ciancanelli, Jeff H Tsai
格式: 文件
语言:English
出版: BMJ Publishing Group 2023-11-01
丛编:Journal for ImmunoTherapy of Cancer
  • 持有资料
  • 实物特征
  • 相似书籍
  • 职员浏览

相似书籍

  • 900 TBio BFX 4101: a neoantigen prioritization pipeline for selected tumor-infiltrating lymphocyte therapy
    由: Quanyuan He, et al.
    出版: (2023-11-01)
  • 346 Expansion and identification of neoantigen reactive tumor infiltrating lymphocytes (TIL) from metastatic colorectal (CRC) and GI cancers
    由: Amy Hall, et al.
    出版: (2023-11-01)
  • Tumor neoantigens and tumor immunotherapies
    由: Wang Jiani, et al.
    出版: (2024-04-01)
  • Screening tumor stage-specific candidate neoantigens in thyroid adenocarcinoma using integrated exome and transcriptome sequencing
    由: Meng Jia, et al.
    出版: (2023-10-01)
  • The interplay between cancer type, panel size and tumor mutational burden threshold in patient selection for cancer immunotherapy.
    由: Mahdi Golkaram, et al.
    出版: (2020-11-01)

检索选项

  • 检索历史
  • 高级检索

查找更多

  • 浏览目录
  • 按字母顺序浏览
  • 探索频道
  • 课程储备
  • 新项目

需要帮助?

  • 检索技巧
  • 咨询台
  • 常见问题